/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Nature·Apr 10

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Researchers are exploring the use of BCL-2 inhibition as a therapeutic strategy in various types of leukemia and lymphoma, including acute lymphoblastic leukemia, mantle cell lymphoma, and chronic lymphocytic leukemia. The approach is being considered for high-risk and relapsed cases, as well as in combination with other therapies such as BTK inhibitors. The effectiveness of BCL-2 inhibition and potential strategies to overcome resistance are being investigated in different clinical scenarios.

Full coverage

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions

Nature·Apr 15

Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia

Frontiers·Feb 25

Adding a BCL-2 Inhibitor to BTK Inhibitor Therapy—Can Lisaftoclax Close the Gap for High-Risk CLL?

Pharmacy Times·May 30

ASCO Treatment Framework for Management of Mantle Cell Lymphoma Calls for Individualized, Risk-Adapted Therapy

The American Journal of Managed Care·May 13

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

Wiley Online Library·Feb 24

How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor

ScienceDirect.com·Oct 23

Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies

www.elsevier.com·Feb 15

Mantle cell lymphoma — State of the art — how to treat mantle cell lymphoma in Poland in 2025?

Via Medica Journals·Oct 22

View original report at Nature ↗

Fetching the latest headlines…